Skip to main content
. Author manuscript; available in PMC: 2018 Nov 12.
Published in final edited form as: JAMA Ophthalmol. 2016 Aug 1;134(8):897–903. doi: 10.1001/jamaophthalmol.2016.1678

Table 4.

Proportion of Aflibercept and Ranibizumab Injections to Bevacizumab Injections by Number of Reported Industry Payments

No. of Reported Industry Payments Injections by Category, Median, % P Value
Aflibercept and Ranibizumab Bevacizumab
0 (n = 1867) 16.5 83.5 <.001
1 (n = 434) 37.0 63.0 <.001
2 (n = 274) 53.9 46.1 .81
3–5 (n = 278) 64.4 35.6 <.001
>5 (n = 158) 78.1 21.9 <.001